A new Score for Predicting Immune Checkpoint Inhibitor-Associated Thrombosis in Cancer Patients
Open Access
- 16 June 2025
- journal article
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 31
Abstract
Purpose: This study aims to develop a scoring system tailored for Asian populations through quantifying VTE risk in a cohort of hospitalized cancer patients receiving immune checkpoint inhibitors. Methods: We retrospectively analyzed 1171 patients treated with PD-1/PD-L1 inhibitors at Zhongshan Hospital (Xiamen), Fudan University between January 2021 and December 2023. We gathered information on every patient from the electronic database of the hospital and follow-up.The collected data were statistically analyzed to obtain risk factors for for VTE and validation of the score. Finally, we validated the precision of the model in prediction. Results: Based on these findings, we developed the L2HSDK score,that identified seven independent risk factors for VTE:liver cancer, smoking, diabetes mellitus, liver dysfunction, cardiovascular history, and a Khorana Risk Score ≥ 3. The patients were divided into low, moderate, and high VTE risk groups. Significant differences in VTE incidence were observed across these groups, with the high-risk group showing a markedly higher risk. The validation of the model demonstrates the precision of the L2HSDK score in prediction. Conclusion: The L2HSDK score offers a more precise and tailored method for assessing VTE risk in cancer patients receiving PD-1/PD-L1 inhibitors therapy in mainland China, surpassing the widely used Khorana Risk Score by accounting for regional and treatment-specific factors.Keywords
This publication has 27 references indexed in Scilit:
- Hyperglycemia: a prothrombotic factor?Journal of Thrombosis and Haemostasis, 2010
- Coagulation dynamics and platelet functions in obstructive jaundiced patientsJournal of Gastroenterology and Hepatology, 2009
- Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer PatientsJAMA, 2008
- Risk factors for chemotherapy‐associated venous thromboembolism in a prospective observational studyCancer, 2005
- Vascular complications in diabetes mellitus: the role of endothelial dysfunctionClinical Science, 2005
- Management of Diabetes and Hyperglycemia in HospitalsDiabetes Care, 2004
- Effects of Lifestyle on Hemostasis, Fibrinolysis, and Platelet ReactivityArchives of internal medicine (1960), 2003
- Diabetes and Endothelial Dysfunction: A Clinical PerspectiveEndocrine Reviews, 2001
- Lifestyle and Hemostatic Risk Factors for Ischemic Heart DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- Activation of the Coagulant Pathway in Cigarette SmokersThrombosis and Haemostasis, 1998